Capital Management, Llc Sto... Net Worth

The estimated Net Worth of Capital Management, Llc Sto... is at least 11.3 百万$ dollars as of 12 May 2017. Capital Sto owns over 510,000 units of Recro Pharma Inc stock worth over 3,975,974$ and over the last 7 years Capital sold REPH stock worth over 7,318,683$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Sto REPH stock SEC Form 4 insiders trading

Capital has made over 3 trades of the Recro Pharma Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Capital sold 510,000 units of REPH stock worth 3,774,000$ on 12 May 2017.

The largest trade Capital's ever made was selling 510,000 units of Recro Pharma Inc stock on 12 May 2017 worth over 3,774,000$. On average, Capital trades about 323,979 units every 3 days since 2017. As of 12 May 2017 Capital still owns at least 1,902,380 units of Recro Pharma Inc stock.

You can see the complete history of Capital Sto stock trades at the bottom of the page.

What's Capital Sto's mailing address?

Capital's mailing address filed with the SEC is 919 NW BOND STREET, SUITE 204, BEND, OR, 97703.

Insiders trading at Recro Pharma Inc

Over the last 11 years, insiders at Recro Pharma Inc have traded over 25,533,136$ worth of Recro Pharma Inc stock and bought 3,055,820 units worth 22,429,197$ . The most active insiders traders include Healthcare Master Fund Ltd ...、Investment Company, Inc. Awm、James E Deerfield Mgmt L.P..... On average, Recro Pharma Inc executives and independent directors trade stock every 31 days with the average trade being worth of 151,953$. The most recent stock trade was executed by J David Jr Enloe on 15 March 2022, trading 512 units of REPH stock currently worth 1,004$.

What does Recro Pharma Inc do?

Recro Pharma Inc. is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.

Complete history of Capital Sto stock trades at Recro Pharma Inc

Recro Pharma Inc executives and stock owners

Recro Pharma Inc executives and other stock owners filed with the SEC include:

• Geraldine Henwood,
  President, Chief Executive Officer, Director
• Ryan Lake,
  Chief Financial Officer
• William Ashton,
  Independent Director
• Wayne Weisman,
  Independent Chairman of the Board
• Winston Churchill,
  Independent Director
• Michael Berelowitz,
  Independent Director
• Ryan D. Lake,
  Chief Financial Officer
• Bryan Reasons,
  Independent Director
• J. David Enloe Jr.,
  Pres, CEO & Director
• Argot Partners,
  IR Contact Officer
• Tim Bourque,
  VP of Operations & Site Head of San Diego
• David Smithwick B.S.,
  VP of Operations & Site Head of Gainesville
• Richard Sidwell Ph.D.,
  VP & Chief Scientific Officer
• Marshall Rizzo M.B.A.,
  Sr. VP & GM
• Randall J. Mack,
  Sr. VP of Devel.
• Erica Raether M.A.,
  VP of People, Culture & ESG
• William Hirschman,
  VP of Sales & Marketing
• Matthew McKendry,
  Director of Accounting
• Laura L. Parks,
  Director
• Karen Flynn,
  Director
• Vitalife Partners Ii Lp Scp,
  10% owner
• Donna Nichols,
  CAO/Controller
• Stewart Mc Callum,
  Chief Medical Officer
• Randall Mack,
  Senior VP, Development
• Fred Graff,
  Chief Commercial Officer
• Capital Management, Llc Sto...,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Vitalife Partners (Israel) ...,
  10% owner
• Alfred Altomari,
  Director
• Healthcare Master Fund Ltd ...,
  
• Diane Myers,
  Senior VP-Reg./Quality
• Jyrki Mattila,
  Executive VP, Business Dev.
• Michael Celano,
  Chief Financial Officer
• Arnaud Ajdler,
  Director
• Abraham Ludomirski,
  Director
• Charles Garner,
  CFO and Chief Business Officer
• J David Jr Enloe,
  Chief Executive Officer
• James Charles Miller,
  Director
• Investment Company, Inc. Awm,
  10% owner